Summary:
«Nyra is developing a transcatheter technology (CARLEN), which modifies the native mitral valve leaflets with a proprietary implant, to correct for deficiencies that otherwise lead to mitral regurgitation, while preserving the physiological valve geometry. «We know today that proper correction of mitral regurgitation in patients surviving with heart failure can reduce mortality and hospitalization rates, with earlier intervention yielding the best results,» says Murali Padala, Ph.D., the inventor of CARLEN, Director of the Carlyle Fraser Cardiothoracic Research Laboratories at Emory University, and founder of Nyra Medical. «CARLEN fills a much-needed gap in safely and effectively correcting mitral regurgitation across different valve anatomies, and offers the benefit of preserving the full range of other transcatheter and surgical treatments as future options. We methodically developed this technology with funding from the Georgia Research Alliance, Coulter Foundation, National Institutes of Health, and the Carlyle Fraser Heart Center at Emory Midtown Hospital, and upon de-risking spun it off into Nyra Medical. We are enthusiastic to partner with this experienced syndicate of investors to build on Nyra’s strong momentum in product development and to advance CARLEN to benefit patients in need.».»
Article written by Bio Space
23|11|2022
Source:
Bio Space